Extended Data Figure 3. Donor-cell-derived MPN is developed in Ptpn11^E76K/+Mx1-Cre⁺ broad knock-in mice and Ptpn11^D61G/+ global knock-in mice, but not Ptpn11^E76K/+Vav1-Cre⁺ haematopoietic cell-specific knock-in mice transplanted with wild-type BM cells.

BM cells (2 × 10⁶) freshly collected from wild-type BoyJ mice (CD45.1⁺) were transplanted into lethally irradiated (1,100 cGy) Ptpn11^E76K/+Mx1-Cre⁺, Ptpn11^+/+Mx1-Cre⁺ (8 weeks after pI–pC administration), and Ptpn11^E76K/+Vav1-Cre⁺ mice at 16-week old (CD45.2⁺). Spleen weights (n = 5 mice per group) (a), percentages of donor cell (CD45.1⁺) reconstitution (n = 8 mice per group) and percentages of donor cell-derived myeloid (Mac-1⁺Gr-1⁺) cells (n = 8 mice per group) in the peripheral blood of the recipients (b) were determined at the indicated time points following the transplantation. c, BM cells (1 × 10⁶) freshly collected from wild-type BoyJ mice (CD45.1⁺) were transplanted into lethally irradiated 3–4-month old Ptpn11^D61G/+ and Ptpn11^+/+ (CD45.2⁺) mice (n = 14 and 17 mice, respectively). Recipients were monitored for MPN development for 8 months. Percentages of donor cell (CD45.1⁺)-derived Mac-1⁺ myeloid cells in the peripheral blood of recipients were determined. Representative results are shown. Data shown in a, b are mean ± s.d. of all mice examined; **P < 0.01; ***P < 0.001. Source Data for this figure are available online.